Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2015

View Archived Issues

Gene editing of human intestinal organoids as a model system for colorectal cancer

MRC Technology and NYU School of Medicine to develop antibody for inflammatory osteolysis

GTx licenses University of Tennessee SARD technology

Chugai Pharmaceutical reports on active first quarter of 2015

Novel PDE10 inhibitor demonstrates highly potent and selective tumor cell growth inhibitory activity

Amgen profiles progress of first quarter 2015

Lack of mitochondrial toxicity of AL-335 and AL-516

Positive European opinion on methylnaltrexone bromide for opioid-induced constipation

In vitro test first to detect psychiatric adverse events of drugs

Phase III success with single-dose dalbavancin regimen for Gram-positive skin infections

FDA accepts AbbVie's NDA for all-oral, interferon-free HCV regimen

MedImmune and Juno Therapeutics partner for immuno-oncology clinical trials

CUPID2 trial of Mydicar fails to meet endpoints

First clinical results on antibacterial OP-0595

Mitotech's antioxidant SkQ1 reduces symptoms of dry eye in phase II trial

R-Tech Ueno acquires rights to DE-105 from Santen Pharmaceutical

FDA approves Cyramza for metastatic colorectal cancer

Nissan Chemical patents new Cav3.2 inhibitors

Amgen discloses Nav1.7 inhibitors

Bayer Schering Pharma reports FXIa inhibitors

A*STAR discloses MNK1 and 2 inhibitors

Daewoong reports discovery of H+/K+-ATPase inhibitors

FDA grants orphan drug designation to GW's cannabidiol for neonatal hypoxic-ischemic encephalopathy

EMA committee recommends approval of Opdivo for advanced melanoma

European committee recommends approval of Hetlioz for non-24-hour sleep-wake disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...